Influenza Clinical Trial
Official title:
Evaluation of Alternative Oseltamivir (Tamiflu[R]) Dosing Strategies for Use During Influenza Prophylaxis
Verified date | September 23, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will determine if oseltamivir (Tamiflu(Registered Trademark)) is safe and
effective given less frequently than the currently prescribed dose of twice a day for 5 days
to people who have the flu, and once a day for up to 6 weeks in people who have been exposed
to someone else with flu and want to prevent getting it themselves. This study will see if
the drug can be given once every other day instead of daily if given with another medication
called probenecid (Benemid(Registered Trademark) or Probalan(Registered Trademark)).
Healthy people 18 years of age and older may be eligible for this study. Candidates are
screened with a medical history, physical examination, and blood and urine tests.
Participants are randomly assigned to one of the following regimens for 2 weeks: 1) 75
milligrams (mg) of oseltamivir once a day; 2) 75 mg of oseltamivir once every other day plus
500 mg probenecid four times a day; or 3) 75 mg of oseltamivir once every other day plus 500
mg probenecid twice a day. All medications are taken by mouth. On study day 0, subjects have
the following baseline procedures: measurement of vital signs, review of medical and
medication history, physical examination, blood draw and urine test. They also receive the
first dose of oseltamivir or oseltamivir and probenecid. In addition, they undergo the
following procedures as follows:
- Days 1 and 4: Vital signs; review of clinical symptoms, side effects and medications
taken; urine testing and blood draw.
- Day 8: Same as day 1 plus count of study medication.
- Day 14: Same as day 8 plus pharmacokinetic study to measure the amount of oseltamivir
and probenecid in the blood. For this test, a catheter is inserted into an arm vein and
blood samples are collected through the catheter before taking the study medications, at
the time the medications are taken, and again at 15 minutes, 30 minutes, 45 minutes and
1, 1.5, 2, 4, 8 and 12 hours after the medication is taken. The catheter is then
removed. This is the last day to take the study medication.
- Day 15: Blood draw for 24-hour (post medication) blood sample.
- Day 16: Blood draw for 48-hour (post medication) blood sample.
- Days 21 and 28: Same as day 1.
Status | Completed |
Enrollment | 48 |
Est. completion date | April 10, 2007 |
Est. primary completion date | April 10, 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: Subjects will include males and non-pregnant females 18 years or older. Subjects who can understand the study and potential safety concerns and can sign the informed consent form prior to admission to this study. Subjects that are willing to complete all the required assessments, tests and evaluations and able to make all study visits. 1. Hemoglobin greater than or equal to 10.0 g/dL for males and greater than 9.0 g/dL for females; 2. Platelet count of greater than or equal to 75,000 /micro L; 3. Absolute neutrophil count greater than or equal to 1000 /micro L; 4. SGOT and SGPT less than 2.5 times normal upper limit; 5. Serum uric acid WNL; 6. Creatinine less than 1.5 times normal upper limit (normal UL 1.5 mg/dL) for the less than 65 years of age group and must be within normal limits for the greater than or equal to 65 years of age group; 7. creatinine clearance greater than or equal to 50 mL/min. EXCLUSION CRITERIA: Subjects with a creatinine clearance of less than 50 mL/min (as measured by the Cockcroft-Gault method) Subjects who are pregnant or breast feeding females Subjects who are not employing adequate contraception Subjects who are drug or alcohol abusers and in the opinion of the investigator would interfere with subject compliance and safety Subjects who are currently participating in any other clinical research study Any acute serious infection requiring prescription therapy within 14 days prior to Day 0 of the study Subjects with G6PD deficiency Subjects who may have been recently exposed to influenza Subjects with gout, blood dyscrasias, or history of hypersensitivity to sulfonamide drugs Subjects with contraindications to the study medications History of allergic reaction to probenecid Have kidney disease, kidney stones, or poorly functioning kidneys Have active peptic ulcer disease On high dose aspirin or any dose non-aspirin salicylate therapy Receiving any of the following medications (relative contraindication for probenecid): Acyclovir, allopurinol, penicillamine, clofibrate, rifampin, methotrexate, zidovudine, theophylline, dapsone, penicillins or cephalosporins, nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Oruvail, Orudis KT), diclofenac (Cataflam, Voltaren), etodolac (Lodine), fenoprofen (Nalfon), flurbiprofen (Ansaid), indomethacin (Indocin), ketorolac (Toradol), nabumetone (Relafen), oxaprozin (Daypro), piroxicam (Feldene), sulindac (Clinoril), tolmetin (Tolectin), and naproxen (Aleve, Anaprox, Naprosyn); a sulfa-based medication such as sulfamethoxazole (Bactrim, Septra, Gantanol), sulfasalazine (Azulfidine), sulfinpyrazone (Anturane), sulfisoxazole (Gantrisin), and others; an oral diabetes medicine such as glipizide (Glucotrol), glyburide (Micronase, Diabeta, Glynase), tolbutamide (Orinase), or tolazamide (Tolinase); a barbiturate such as phenobarbital (Luminal, Solfoton), amobarbital (Amytal), secobarbital (Seconal), and others; or a benzodiazepine (used to treat anxiety and panic disorders and to induce sleep) such as alprazolam (Xanax), diazepam (Valium), lorazepam (Ativan), temazepam (Restoril), chlordiazepoxide (Librium), clonazepam (Klonopin), clorazepate (Tranxene), oxazepam (Serax), estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), or triazolam (Halcion). |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
United States | Brooke Army Medical Center | Houston | Texas |
United States | VA Greater Los Angeles Healthcare System | Los Angeles | California |
United States | VA Palo Alto Health Care System | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Osterholm MT. Preparing for the next pandemic. N Engl J Med. 2005 May 5;352(18):1839-42. — View Citation
Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature. 2005 Oct 6;437(7060):889-93. — View Citation
Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solórzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, García-Sastre A. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005 Oct 7;310(5745):77-80. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |